United Press International - Health Business News Archive
Comprehensive reports and health tips written by our well-known experts.
http://www.upi.com/rss/feedhome/upi_HealthBusiness.rss
Page: 2 of 27 
- Dems blast Medicare Rx on its first day
- Myriad's Flurizan shows promise in phase 2
- New flu test out soon
- Coffee raises fetal death rate -- study
- Health savings accounts catching on
- Women overlooked for CRT therapy
- GSK malaria vaccine may protect long term
- Heart drug flops in study
- Gilead, Roche patch up Tamiflu spat
- New poll on Rx benefit is positive
- Study: Can sperm mimic embryo stem cells?
- Endo's Lidoderm may compete for COX-2 void
- WHC heart pump extends life -- study
- Groups urge patient control of records
- Study confirms lipid drugs' low risk
- Rosy Phase 1 results for ImmunoGen drug
- Human Genome arthritis drug hitting marks
- HIV rates down in African-Americans
- Congress mulls MD Medicare payment fixes
- Group seeks blockage of vaccine bills
- Health experts probe Tamiflu deaths
- CMS chief denies Plan B communications
- HIV diagnoses down in African-Americans
- GOP revolt kills health spending in House
- FDA looks to move beyond black-box warning
- Study to test GI drug in autistic kids
- Fear of suits delaying bird flu vaccine?
- Med SWAT teams proposed by Frist
- Broad stockpiling advised for pandemic
- Abbott HIV drug zaps viral loads in trial
- Glaxo HIV drug gets label update
- Flu stockpiles need ancillary products
- Indian healthcare strained by foreigners
- Grassley renews calls for FDA reform
- One-third of cancer deaths preventable
- Advair warning won't dent sales -- analyst
- FDA should reject Pargluva -- group
- BMS' dasatinib expected to rival Gleevec
- FDA clears Wyeth panic-disorder drug
- U.K. mulls medical data sharing
- FDA approves Par's generic Zofran
- Medicis rejects Mentor's buyout bid
- FDA names new women's health chief
- Emergent's typhoid vaccine in phase 2
- Pfizer wins patent suit against Teva
- U.K. nix of Alzheimer drugs draws fire
- Study shows stress/cholesterol link
- Medicis asks Inamed to nix Allergan offer
- FDA approves St. Francis' X-STOP implant
- USDA bird-flu system action-ready
- Risperdal, Geodon face tough generics
- FDA seeks additional trial for Vasovist
- Study targets placebo effect
- German Merck's CEO resigns
- Heartland home to novel records effort
- Alexion disappoints in Phase 3 trial
- Peregrine enters $6.7M financing deal
- Group decries Bush HIV policy in Africa
- Scientist faults Bush's stem-cell policy
- More tailored therapy for kids' cancers?
- Human, HCA sign two-year deal
- Merck to restructure, cut jobs
- Neck stents help mental function, study
- FDA approves higher dose of Fosrenol
- Buttock fat hinders injectables, study
- Enbrel, Humira to dominate TNF-alpha field
- Schering, Philips strike imaging deal
- Rx plans drive CA Medicare market
- Am Pharm Partners to merge with parent
- Study gives long-term view of diabetes care
- New technology could lessen breast biopsy
- Virtual colonoscopy gets help via computer
- Brain scans link pot, schizophrenia
- Coffee improves short-term memory
- Ranbaxy to launch HIV drug combo in India
- Wellpoint names Larry Glasscock new CEO
- Group charges meager progress on AIDS
- Generic Risperdal to impact anti-psychotics
- Antibody zaps anthrax without antibiotics
- 'Yuck factor' helps health plans save?
- French docs perform first face transplant
- E-prescribing to get boost from drug plan
- Roche, BioCryst team on autoimmune drug
- Ultrasound smokes out fibroids
- Par poised to launch generic Dostinex
- Rigel allergy drug fades in Phase 2 trial
- Conor to expand CoStar/Taxus stent study
- Boston Scientific offers to buy Guidant
- Mesh graft treats spine fracture
- X-rays fail to pinpoint avian flu -- study
- FDA panel backs patch for ADHD
- Ligand platelet drug promising in trials
- Study: gums linked to heart disease
- I-Flow gets nod for anti-microbe catheter
- FDA clears Chiron's West Nile Virus test
- Dialysis drug is cost effective, study
- Wyeth awarded $32 M for HIV vaccine
- Wyeth, Teva OK'd to settle patent suit
- Report says bird flu could cost 5% of GDP
- States say flu preparedness funds lacking